1,2,3,4-四氢-1-萘甲胺 | 91245-72-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 1,2,3,4-四氢-1-萘甲胺
• 英文名称: (+/-)-1-(aminomethyl)-1,2,3,4-tetrahydronaphthalene
• 英文别名: 1,2,3,4-tetrahydro-1-naphthalenemethanamine；C-(1,2,3,4-tetrahydro-[1]naphthyl)-methylamine；C-(1,2,3,4-Tetrahydro-[1]naphthyl)-methylamin；1-Aminomethyl-1.2.3.4-tetrahydro-naphthalin；(Tetralyl-(1)-methyl)-amin；1-Aminomethyl-tetralin；1,2,3,4-Tetrahydronaphthalen-1-ylmethylamine；1,2,3,4-tetrahydronaphthalen-1-ylmethanamine
• CAS: 91245-72-6
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: FSEUPTSLGGJFNX-UHFFFAOYSA-N

物化性质

• 沸点：
  273 ºC
• 密度：
  1.001
• 闪点：
  124 ºC

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢-1-萘甲胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 水 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 2.5h， 生成 3-[(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)amino]pyridine-4-carboxylic acid
  参考文献：
  名称：

  [EN] HISTONE DEMETHYLASE INHIBITORS
  [FR] INHIBITEURS D'HISTONE DÉMÉTHYLASE

  摘要：

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了取代的吡啶或吡啶二氮杂环衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。

  公开号：

  WO2014100818A1
• 作为产物：
  描述：

  氰基萘 在 乙醇 、 sodium 作用下， 生成 1,2,3,4-四氢-1-萘甲胺
  参考文献：
  名称：

  Asphalt production technology. Recent history and old problems

  摘要：

  The study of the history of engineering is not. only due to purely cognitive interest in the past but also to the realization of a fact which has finally become inarguable to us: "one who does not know the past will not see the future. " This article is dedicated to the development of domestic asphalt production technology in rite final third of the century. The subject and time were selected for both subjective and objective reasons. On one hand, we have not only been witnesses to but also participants in the events that rook place in this area in the indicated period of time. On the other hand, the properties of the initial feedstock changed significantly during this period (mixed West Siberian crudes became the fundamental feedstock), which exacerbated the existing process problems and stimulated attempts to solve thr,ll. Data from monographs and reviews published in the central press and articles from the journals Khimiya i Tekhnologiya Topliv i Masel [Chemistry and Technology of Fuels and Oils] and Neftepererabotka i Neftekhimiya [Petroleum Refining and Petrochemistry] were used, since the most important events and findings must have been included in these publications. Great attention is focused on the developments which significantly affected the subsequent evolution of asphalt production technology.

  DOI：

  10.1007/bf02742835

文献信息

• Direct Access to Primary Amines from Alkenes by Selective Metal‐Free Hydroamination
  作者：Yi‐Dan Du、Bi‐Hong Chen、Wei Shu

  DOI：10.1002/anie.202016679

  日期：2021.4.26

  selective synthesis of primary amines from easily available precursors is attractive yet challenging. Herein, we report the rapid synthesis of primary amines from alkenes via metal‐free regioselective hydroamination at room temperature. Ammonium carbonate was used as ammonia surrogate for the first time, allowing for efficient conversion of terminal and internal alkenes into linear, α‐branched, and α‐tertiary

  由容易获得的前体直接和选择性合成伯胺是有吸引力的，但仍具有挑战性。在此，我们报道了室温下通过无金属的区域选择性加氢胺从烯烃快速合成伯胺的方法。碳酸铵首次用作氨替代物，可在温和条件下将末端和内部烯烃有效转化为线性，α支化和α叔伯胺。该方法提供了一种直接而有效的方法，可用于制药化学和其他领域特别感兴趣的各种先进的，高度官能化的伯胺。
• [EN] BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLYL-MÉTHYLURÉE EN TANT QU'AGONISTES DU RÉCEPTEUR ALX
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015019325A1

  公开（公告）日：2015-02-12

  The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  本发明涉及式(I)的苯并咪唑基甲基脲衍生物，其中n、D、E、R1、R2、R3、R4、R6、R7、R8和R9如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。
• Anodic benzylic C(sp³)–H amination: unified access to pyrrolidines and piperidines
  作者：Sebastian Herold、Daniel Bafaluy、Kilian Muñiz

  DOI：10.1039/c8gc01411f

  日期：——

  important heterocyclic motifs of pyrrolidines and piperidines within a uniform reaction protocol. The mechanism of this unprecedented C–H amination strategy involves anodic C–H activation to generate a benzylic cation, which is efficiently trapped by a nitrogen nucleophile. The applicability of the process is demonstrated for 40 examples comprising both 5- and 6-membered ring formations.

  开发了一种电化学脂肪族CH胺化策略，以在统一的反应方案中访问吡咯烷和哌啶的重要杂环基序。这种前所未有的C–H胺化策略的机制涉及阳极C–H活化以生成苄基阳离子，该阳离子被氮亲核试剂有效捕获。对于包含5元和6元环形成的40个实例证明了该方法的适用性。
• DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION
  申请人：Sonesson Clas

  公开号：US20100179211A1

  公开（公告）日：2010-07-15

  The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.

  本发明涉及利用增加哺乳动物大脑脑皮层区域儿茶酚胺、多巴胺和去甲肾上腺素的细胞外水平的化合物，更具体地涉及利用3-二取代苯基-1-吡咯烷醇治疗中枢神经系统疾病。
• Serotonin receptor affinity of cathinone and related analogs
  作者：Richard A. Glennon、Stephen M. Liebowitz

  DOI：10.1021/jm00346a012

  日期：1982.4

  A series of cathinone (alpha-aminopropiophenone) analogues was examined using the isolated rat fundus preparation. (S)-(-)-Cathinone possesses twice the serotonin receptor affinity of (+/-)-cathinone and four times the affinity of racemic amphetamine. Several derivatives of cathinone were found to either possess a lower affinity than the parent compound or did not interact with the receptors in a competitive

  使用分离的大鼠眼底制剂检查了一系列的卡西酮（α-氨基苯乙酮）类似物。（S）-（-）-Cathinone的血清素受体亲和力是（+/-）-Cathineone的两倍，外消旋苯丙胺的亲和力是其四倍。发现卡西酮的几种衍生物要么具有比母体化合物更低的亲和力，要么不以竞争方式与受体相互作用。几种新的类似物1-（氨基甲基）-3,4-二氢萘盐酸盐（3），4-（氨基甲基）-3-色烯盐酸盐（4b）及其6-甲氧基衍生物a与血清素受体相互作用，但以最有可能与取代的卡西酮类似物的相互作用不同的方式。